Indefinite Delivery Contract SPE2DU26D9523

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was awarded a single-award Indefinite Delivery Contract (IDC) by the Defense Logistics Agency on December 4, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The contract, designated SPE2DX, carries a ceiling value of $5.0 million and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. As the prime contractor, DMS Pharmaceutical Group is authorized to provide comprehensive pharmaceutical supply services to Department of Defense healthcare facilities worldwide, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's product portfolio encompasses oncology treatments such as Keytruda and Tecentriq, immunosuppressants and biologic agents including Nucala and Stelara, emergency medications such as epinephrine auto-injectors, specialty surgical products, contraceptive devices, and routine pharmaceuticals spanning antibiotics, antivirals, pain management drugs, and other essential medications.

The underlying Pharmaceutical Prime Vendor Global Program Generation V solicitation, posted as a pre-solicitation notice on February 1, 2024, was designed to establish a multi-regional pharmaceutical supply framework with an estimated total procurement value of $30.3 billion across the Defense Logistics Agency's Troop Support Medical Supply Chain. The contracting strategy contemplated multiple awards on a regional basis with at least three different contractors designated across North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items, with awards based on technical acceptability and lowest overall price using distribution fee methodology. The DMS Pharmaceutical Group contract operates within this larger acquisition framework, with firm fixed-price delivery orders issued as needed to support recurring medical supply requirements and contingency operations for Department of Defense military healthcare operations globally. No set-aside provisions were applied to either the original solicitation or the resulting contract award.